Upstream Bio, Inc. UPB
3.23 USD +0.02 (+0.62%)
At closeNov 6, 2026, 4:00 PM EST
3.23 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
3.02 Day range 3.28
2.74 52-week range 32.60
- YTD
- -88.10%
- 1 year
- -86.35%
- Market cap
- 176.91M
- Revenue (ttm)
- 2.85M
- EPS (ttm)
- -2.88
- Shares out
- 54.04M
- Forward P/E
- -2.45
- YTD return
- -88.10%
- 1-year return
- -86.35%
- Volume
- 1.14M
- Avg volume
- 868.08K
- Open
- 3.24
- Previous close
- 3.21
- Day's range
- 3.02 – 3.28
- 52-week range
- 2.74 – 32.60
- Analysts
- Strong Buy
- Price target
- 47.86 (+1381.6%)
ALL -18.77 (-85.32%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 164.16
- Price / book
- 1.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.00%
- Free cash flow
- 0
- Total cash
- 341.51M
- Total debt
- 1.27M
- Return on equity
- -35.44%
- Short % of float
- 15.85%
- 50-day average
- 18.55
- 200-day average
- 19.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.86 +1381.6% upside
Now 3.23
- Target (low)
- 35.00
- Target (mean)
- 47.86
- Target (high)
- 75.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.76667.
Financials — quick view
UPB Revenue — quarterly 773.00K
UPB Net income — quarterly -39.70M
UPB EPS — quarterly -0.73
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 18, 2025 | Mizuho | init | — | Outperform |
| Dec 2, 2025 | LifeSci Capital | init | — | Outperform |
| Nov 18, 2025 | Evercore ISI Group | init | — | Outperform |
| Oct 14, 2025 | Truist Securities | init | — | Buy |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- upstreambio.com
News
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target 
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9 
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25 
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate 
Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP Patients Achieved Clinically Meaningful Nasal Polyp Score Improvements Versus 24% On Placebo - JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8
12 Health Care Stocks Moving In Wednesday's After-Market Session - Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation
- HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36
Upstream Bio Presents New Data From Phase 2 VIBRANT Trial Evaluating Verekitug In Participants With Chronic Rhinosinusitis With Nasal Polyps At ATS 2026 International Conference
Your note
Sign in to keep a note on UPB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AI UPSTREAM LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| AMBROSE ALLISON | General Counsel | Sale | Mar 15, 2026 | 16,525 |
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| DEYKIN AARON M.D. | Officer | Sale | Mar 15, 2026 | 32,687 |
| GRAY MICHAEL P | Chief Operating Officer | Sale | Mar 15, 2026 | 29,648 |
| HOUGHTON ADAM | Officer | Sale | Mar 15, 2026 | 24,301 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.91% | 7,518,202 | 65.18M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 10.54% | 5,693,589 | 49.36M | Dec 30, 2025 |
| Blackrock Inc. | 6.19% | 3,344,504 | 29.00M | Dec 30, 2025 |
| Decheng Capital LLC | 5.82% | 3,143,078 | 27.25M | Dec 30, 2025 |
| NORGES BANK | 5.33% | 2,882,647 | 24.99M | Dec 30, 2025 |
| Enavate Sciences Gp, LLC | 4.55% | 2,459,703 | 21.33M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,443,025 | 12.51M | Dec 30, 2025 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.54% | 1,371,372 | 11.89M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.48% | 800,000 | 6.94M | Jan 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.44% | 780,261 | 6.76M | Jan 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.28% | 691,003 | 5.99M | Jan 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.26% | 682,018 | 5.91M | Dec 30, 2025 |